Profound Medical reports Q2 EPS (28c), consensus (29c)

Reports Q2 revenue $2.23M, consensus $2.59M. “While we continue to make strong commercial progress, in some ways we are just approaching the starting line as we make final preparations for the permanent CPT(R) Category 1 codes for TULSA going into effect at the beginning of 2025, an anticipated major inflection point for our business,” said Arun Menawat, Profound’s CEO and Chairman. “Adequate reimbursement is generally considered essential for treatment technology innovators like Profound to drive forward widespread adoption and, importantly, we believe CMS’ proposed rule for TULSA will put us on at least a level playing field with competing current standard-of-care and other prostate disease treatment modalities.”